LU86184A1 - FOOD SUPPLEMENT COMPOSITION FOR NATUROTHERAPY - Google Patents
FOOD SUPPLEMENT COMPOSITION FOR NATUROTHERAPY Download PDFInfo
- Publication number
- LU86184A1 LU86184A1 LU86184A LU86184A LU86184A1 LU 86184 A1 LU86184 A1 LU 86184A1 LU 86184 A LU86184 A LU 86184A LU 86184 A LU86184 A LU 86184A LU 86184 A1 LU86184 A1 LU 86184A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- ash
- leaves
- naturotherapy
- food supplement
- supplement composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 21
- 235000015872 dietary supplement Nutrition 0.000 title description 3
- 230000007935 neutral effect Effects 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- 229910021538 borax Inorganic materials 0.000 claims description 2
- 230000000762 glandular Effects 0.000 claims description 2
- 239000004328 sodium tetraborate Substances 0.000 claims description 2
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 2
- 230000036642 wellbeing Effects 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 244000181980 Fraxinus excelsior Species 0.000 description 3
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000015092 herbal tea Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- -1 stearate anions Chemical class 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241001634820 Campaea Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100102624 Drosophila melanogaster Vinc gene Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241001536358 Fraxinus Species 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000830631 Ircinia campana Species 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000842783 Orna Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000442474 Pulsatilla vulgaris Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Injection Moulding Of Plastics Or The Like (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
L-3081L-3081
" Η~Π 1 A GRAND-DUCHÉ DE LUXEMBOURG"Η ~ Π 1 IN GRAND-DUCHY OF LUXEMBOURG
Brevet N° V *...........V "JPatent N ° V * ........... V "J
du 2.7.....novembre 1985 ¢1¾¾¾ Monsieur le Ministre de l’Économie et des Classes Moyennesfrom 2.7 ..... November 1985 ¢ 1¾¾¾ Dear Minister of the Economy and the Middle Classes
Titre délivré ................... Service de la Propriété IntellectuelleTitle issued ................... Intellectual Property Service
WvM? LUXEMBOURGWvM? LUXEMBOURG
Demande de Brevet d’invention I. Requête CAMPANA Francine, "Le Mercator", 7 rue de l'Industrie, Prin- ^ cipauté de Monaco, représentée par Monsieur Jean Waxweiler,____ 21-25 Allée Scheffer, Luxembourg, agissant en qualité de man-^ dataire....................................................................................................................................................................................................................................______ dépose(nt) ce vinc^-sept n°vsnbre ^ neuf cent qimtre-vingt-cirKj U|3} à ..15.,..00______heures, au Ministère de l’Économie et des Classes Moyennes, à Luxembourg : :H;$t v 1. la présente reauêtejoour l’obtention d’un brevet d’invention concernant:Invention Patent Application I. CAMPANA Francine Application, "Le Mercator", 7 rue de l'Industrie, Principality of Monaco, represented by Jean Waxweiler, ____ 21-25 Allée Scheffer, Luxembourg, acting as Mandate ^ .............................................. .................................................. .................................................. .................................................. ................................______ remove (s) this vinc ^ -sept n ° vsnbre ^ neuf cent qimtre- twenty-cirKj U | 3} at ..15., .. 00______hours, at the Ministry of the Economy and the Middle Classes, in Luxembourg:: H; $ tv 1. this reauêtejoour obtaining a patent of invention relating to:
Composition de complémentalimentaire pour naturothérapie •..................................................................................................................................................................................—.....................-.................-m*Complementary food composition for naturotherapy • ............................................ .................................................. .................................................. .................................. — ............... ......-.................- m *
2. la délégation de pouvoir, datée de Monaco............................... le 1 P pn\romKr-o 1 pRR2. the delegation of power, dated from Monaco ............................... 1 P pn \ romKr-o 1 pRR
3. la description en langue ...française.............................de l'invention en deux exemplair«·, 4.............../...............planches de dessin, en deux exemplaires; 5. la quittance des taxes versées au Bureau de l’Enregistrement à Luxembourg, .. f; ^ le vingt-sept novembre mil neuf cent quatre-vingt-cinq ..............................................3. description in language ... French ............................. of the invention in two examples «·, 4 ............... / ............... drawing boards, in two copies; 5. the receipt of taxes paid to the Luxembourg Registration Office, .. f; ^ November 27, nineteen hundred and eighty-five .................................... ..........
déclare(nt) en assumant la responsabilité de cette déclaration, que l’(es) inventeurs) ....CAMBANA....Er.ancine.,......"Le ..Mercator.."..,.......7.....r.ue. de.....l'Industrie.,.................declares (s) assuming responsibility for this declaration, that the inventor (s)) .... CAMBANA .... Er.ancine., ...... "Le ..Mercator .." .. , ....... 7 ..... r.ue. Of the industry.,.................
revendique(nt) pour la susdite demande de brevet la priorité d’une (des) demande(s) le 18.....novembre 1985 sous.....le No......85/17119 _ ....claims (s) for the above patent application the priority of one (s) application (s) on 18 ..... November 1985 under ..... No ...... 85/17119 _. ...
......
au nom de ...CAMPAEA....Franc.ine......................................................................................................................................................................on behalf of ... CAMPAEA .... Franc.ine .................................... .................................................. .................................................. ..............................
élit(élisent) pour lui (elle) et, si désigné, pour son mandataire, à Luxembourg..............._.. jf._elect (elect) for him / her and, if appointed, for his / her representative, in Luxembourg ..............._ .. jf._
Jean Waxweixer, 21-25 Allée Scheffer, Luxembourg ^ sollicite(nt) la délivrance d’un brevet d’invention pour l'obi et décrit et représenté dans les annexes susmentionnées, — avec ajournement de cette délivrance a mois. (Π)Jean Waxweixer, 21-25 Allée Scheffer, Luxembourg ^ requests (s) the issue of a patent for invention for the obi and described and represented in the abovementioned appendices, - with adjournment of this issue to months. (Π)
Le ; mandataire .........................The ; agent .........................
; ·-· f f ; , _t - ·, ......................À—..........................; · - · f f; , _t - ·, ...................... TO —..................... .....
i II. Procès-verbal de Dépôti II. Deposit Minutes
La susdite demande de brevet d’invention a été déposée au Ministère de l’Économie et des Classes Moyennes, Service de la Propriété Intellectuelle à Luxembourg, en date du : IS W Pr. le Ministre .JV, à .t.*?./. y heures I | T. \ de l’Économie et des^ Classes Moyennes,The above application for a patent for invention has been filed with the Ministry of the Economy and the Middle Classes, Intellectual Property Service in Luxembourg, on: IS W Pr. The Minister .JV, at .t. * ?. /. y hours I | T. \ of Economy and ^ Middle Classes,
\ nUj-' .Τ’ J#t ~J\ nUj- '.Τ ’J # t ~ J
/ " ^ \S/··· ‘ ' A 68007 REVENDICATION DE PRIORITÉ Dépôt de la demande de brevet en France ç|y 18 novembre 1985 SOUS le numéro 85/17119/ "^ \ S / ···‘ 'A 68007 CLAIM OF PRIORITY Filing of the patent application in France ç | y November 18, 1985 UNDER number 85/17119
MEMOIRE DESCRIPTIF DEPOSE A L'APPUI D'UNE DEMANDE DE BREVET D'INVENTION AU GRAND-DUCHE DE LUXEMBOURGDESCRIPTIVE MEMORY FILED IN SUPPORT OF A PATENT INVENTION APPLICATION IN THE GRAND DUCHY OF LUXEMBOURG
par; CAMPANA Francine pour; Composition de complément alimentaire pour naturothérapie v <►>>by; CAMPANA Francine for; Food supplement composition for naturotherapy v <► >>
La présente invention concerne une nouvelle composition médicamenteuse dont l'ensemble des activités peut être exprimée ‘ par l'expression "équilibrant psycho-somatique".The present invention relates to a new drug composition, all of whose activities can be expressed ‘by the expression" psycho-somatic balancing ".
Cette composition exerce en effet les activités 5 principales suivantes : -rejet des surcharges de toutes natures, à savoir diurèse, fonctions intestinales, fonctionnement des glandes sudoripares et sébacées ; - assimilation des vitamines et oligo-éléments, 10 “ transfert des états psychiques morbides (agressivité, dépressivité) en états normaux sans effets secondaires ou inversés.This composition in fact exercises the following 5 main activities: -rejection of overloads of all kinds, namely diuresis, intestinal functions, functioning of the sweat and sebaceous glands; - assimilation of vitamins and trace elements, 10 “transfer of morbid mental states (aggressiveness, depressiveness) into normal states without side effects or reversed.
Cet ensemble complexe d'actions se traduit par une sensation globale d'équilibre et de bien être qu'aucun médicament 15 individuel ne permet d'atteindre.This complex set of actions results in an overall feeling of balance and well-being that no individual drug can achieve.
Ce but se trouve atteint grâce à la présence, dans cette composition, d'une proportion déterminée de feuilles de frêne à l'état pulvérulent.This object is achieved thanks to the presence, in this composition, of a determined proportion of ash leaves in the pulverulent state.
Le frêne dont les feuilles sont ainsi utilisées est de 2o préférence celui du genre Fraxinus excelsior L., qui se développe largement dans les régions méditerranéennes, et qui a été depuis l'Antiquité reconnu pour ses vertus, largement appliquées dans les médecines populaires traditionnelles. Ainsi les tisanes de feuilles de frêne étaient considérées comme une boisson de 25 jouvence pour les arthritiques et les goutteux.The ash whose leaves are thus used is 2o preferably that of the genus Fraxinus excelsior L., which grows widely in the Mediterranean regions, and which has been recognized since Antiquity for its virtues, widely applied in traditional folk medicines. Thus the ash leaf herbal teas were considered to be a youthful drink for arthritis sufferers and gouty people.
D'autres espèces de frêne peuvent être utilisées selon les régions, par exemple le Fraxinus Orna et le frêne à manne.Other ash species can be used depending on the region, for example the Fraxinus Orna and the manna ash.
Toutefois, de telles tisanes ne repésentaient que des extraits aqueux ne contenant qu'une portion des constituants 30 actifs utiles, à savoir celle soluble à l'eau chaude, les autres n'ayant jamais été exploités jusqu'à ce jour, ni même entièrement identifiés. En fait, les analyses connues concernant la présence dans les feuilles de frêne de différents composés chimiques sont * toutes très anciennes et assez vagues. Seuls quelques auteurs de 35 la fin du xix ème siècle ont pu reconnaîitre dans ces feuilles à côté de tels minéraux, des sucres tels que l'inositol, le mannitol, le dextrose et du quercitroside, ainsi que de l'acide malique, des gommes de l'acide tannique, des huiles terpéniques, des diastases et des substances organiques non identifiées. On peut à bon droit considérer que seuls les sucres étaient 2 effectivement extraits et représentaient la "tisane", tandis que les gommes, terpènes et autres composants organiques ont toujours été écartés avec les résidus minéraux.However, such herbal teas represented only aqueous extracts containing only a portion of the useful active constituents, namely that which is soluble in hot water, the others having never been used to date, or even entirely identified. In fact, the known analyzes concerning the presence in the leaves of ash of various chemical compounds are * all very old and rather vague. Only a few authors from the end of the 19th century were able to recognize in these leaves, alongside such minerals, sugars such as inositol, mannitol, dextrose and quercitroside, as well as malic acid, gums tannic acid, terpene oils, diastases and unidentified organic substances. It can rightly be considered that only the sugars were actually extracted and represented "herbal tea", while the gums, terpenes and other organic components were always discarded with the mineral residues.
Ce sont ces composants organiques qui donnent aux 5 compositions selon l'invention toute leur originalité.It is these organic components which give the compositions according to the invention all their originality.
L'invention consiste donc à utiliser comme principe actif principal dans une composition médicamenteuse à action équilibrante psycho-somatique, des feuilles de frêne de la variété Fraxinus Excelsior à l'état pulvérisé et sans aucun ^0 traitement de purification ou d'extraction préalable.The invention therefore consists in using as main active principle in a medicinal composition with a psycho-somatic balancing action, ash leaves of the variety Fraxinus Excelsior in the pulverized state and without any prior purification or extraction treatment.
Les compositions selon l'invention contiennent par ailleurs un certain nombre de constituants à caractère secondaire, à savoir des sels métalliques, et notamment du chlorure de sodium, du tartrate neutre de potassium, du stéarate x5 de magnésium et du bicarbonate de sodium, utiles dans l'action équilibrante de la composition par l'apport des anions tartrate et stéarate sur son mécanisme d'action.The compositions according to the invention also contain a certain number of constituents of secondary nature, namely metal salts, and in particular sodium chloride, potassium neutral tartrate, magnesium stearate x5 and sodium bicarbonate, useful in the balancing action of the composition by the contribution of the tartrate and stearate anions on its mechanism of action.
Selon un exemple de réalisation, les compositions selon l'invention peuvent contenir : 20 Feuilles de Fraxinus excelsior L. pulvérisées 2,5-3,5According to an exemplary embodiment, the compositions according to the invention can contain: 20 leaves of Fraxinus excelsior L. pulverized 2.5-3.5
Chlorure de magnésium 3,0-4,0Magnesium chloride 3.0-4.0
Tartrate neutre de potassium 3,0-4,0Neutral potassium tartrate 3.0-4.0
Stéarate de magnésium 2,0-3,0Magnesium stearate 2.0-3.0
Borax officinal neutre 15,0-20,0 25 Bicarbonate de sodium complément à 100.Borax officinal neutral 15.0-20.0 25 Sodium bicarbonate supplement to 100.
De telles compositions, administrées sous forme de comprimés, exercent sur l'organisme les actions bénéfiques rappelées ci-dessus, en déterminant en même temps chez le sujet une amélioration marquée du psychisme par la disparition des état 30 de "stress", se traduisant selon les sujets, par une dépréssion ou une agressivité pathologiques. Cette disparition ne s'accompagne ni d'effets secondaires fâcheux, ni d'une inversion de symptômes, ce qui est l'inconvénient fréquent des médicaments de ce genre.Such compositions, administered in the form of tablets, exert on the organism the beneficial actions recalled above, by determining at the same time in the subject a marked improvement in the psyche by the disappearance of the states of "stress", resulting in subjects, by pathological depression or aggression. This disappearance is not accompanied by unfortunate side effects, nor by a reversal of symptoms, which is the frequent drawback of drugs of this kind.
35 On peut d'ailleurs avec une certaine vraisemblance, rapproche ces résultats, obtenus sous contrôle scientifique „ médical, des vertus légendaire attribuées au frêne dans l'Antiquité mythologique, notamment grecque.35 We can, moreover, with a certain likelihood, compare these results, obtained under scientific medical supervision, with the legendary virtues attributed to ash in mythological Antiquity, notably Greek.
Les indications des compositions selon l'invention sont donc de nature double et complémentaire : 3 - d’une part pour les traitements ayant pour objectif le rejet des surcharges, par l'amélioration des fonctions naturelles, y compris toutes les fonctions glandulaires, et par l'amélioration et l'assimilation des vitamines et oligo-éléments.The indications for the compositions according to the invention are therefore of a double and complementary nature: 3 - on the one hand for treatments having the objective of rejecting overloads, by improving the natural functions, including all the glandular functions, and by improvement and assimilation of vitamins and trace elements.
5 - d'autre part pour les traitements de transfert des états psychiques morbides, du type agressivité, dépressivité, en vue de créer chez le sujet une sensation globale d'équilibre et de bien être.5 - on the other hand for the treatments of transfer of the morbid psychic states, of the type aggressiveness, depressiveness, in order to create in the subject a global feeling of balance and well being.
Il convient de noter objectivement que le traitement de 10 certains patients par ces compositions peut déterminer chez eux des phénomènes temporaire de sécrétions très odorants (transpiration, urines) ou même de déchets gras sous forme de boutons sur le visage ou le dos.It should be objectively noted that the treatment of certain patients with these compositions can cause temporary phenomena of very odorous secretions (perspiration, urine) or even fatty waste in the form of pimples on the face or the back.
Ces sécrétions sont aisément éliminées par exemple par un 15 bain à la racine d'ortie.These secretions are easily removed, for example by a bath with nettle root.
Bien que assez déplaisants, ces phénomènes illustrent le très fort degré d'activité des compositions selon l’invention et, du fait que le “thé de jouvence" extrait de frêne de la médecine populaire ne les déclenchait pas, ils illustrent également la 20 différence de nature, d'action et d’effets des compositions selon l'invention par rapport à ce "thé de jouvence".Although rather unpleasant, these phenomena illustrate the very high level of activity of the compositions according to the invention and, since the "tea of youth" extracted from ash of popular medicine does not trigger them, they also illustrate the difference of nature, action and effects of the compositions according to the invention with respect to this "tea of youth".
On peut ajouter à ces compositions des sucres pharmaceutiques, tels que le lactose, le glycocolle et analogues, ainsi que des parfums neutres pulvérulents, notamment des fruits 25 lyophilisés.Pharmaceutical sugars, such as lactose, glycocolle and the like, as well as powdery neutral flavors, especially freeze-dried fruits, can be added to these compositions.
Ces compositions peuvent ainsi être assimilées aux compléments alimentaires utilisés en naturopathie et naturothéraphie.These compositions can thus be assimilated to food supplements used in naturopathy and naturotherapy.
3030
Claims (4)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8517119A FR2590171B1 (en) | 1985-11-18 | 1985-11-18 | FOOD SUPPLEMENT COMPOSITION FOR NATUROTHERAPY |
FR8517119 | 1985-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
LU86184A1 true LU86184A1 (en) | 1986-03-24 |
Family
ID=9324977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU86184A LU86184A1 (en) | 1985-11-18 | 1985-11-27 | FOOD SUPPLEMENT COMPOSITION FOR NATUROTHERAPY |
Country Status (10)
Country | Link |
---|---|
BE (1) | BE903736A (en) |
CA (1) | CA1271424A (en) |
CH (1) | CH667011A5 (en) |
DE (1) | DE3545620A1 (en) |
FR (1) | FR2590171B1 (en) |
GR (1) | GR852917B (en) |
IT (1) | IT1191985B (en) |
LU (1) | LU86184A1 (en) |
NL (1) | NL8602784A (en) |
PT (1) | PT81631B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRPK20060416B3 (en) * | 2006-11-29 | 2010-04-30 | Juroš Ante | Herbal mixture and an active substance originating thereof, for enhancing immunity and improving medical treatment |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2059972A1 (en) * | 1969-08-11 | 1971-06-11 | Nicolas Roland | Antirheumatic, antideafness extract of ashes of the ash-tree |
-
1985
- 1985-11-18 FR FR8517119A patent/FR2590171B1/en not_active Expired
- 1985-11-27 LU LU86184A patent/LU86184A1/en unknown
- 1985-11-29 BE BE2/60857A patent/BE903736A/en not_active IP Right Cessation
- 1985-12-04 GR GR852917A patent/GR852917B/el unknown
- 1985-12-09 PT PT81631A patent/PT81631B/en not_active IP Right Cessation
- 1985-12-21 DE DE19853545620 patent/DE3545620A1/en not_active Withdrawn
-
1986
- 1986-01-08 IT IT67010/86A patent/IT1191985B/en active
- 1986-01-14 CH CH116/86A patent/CH667011A5/en not_active IP Right Cessation
- 1986-02-07 CA CA000501418A patent/CA1271424A/en not_active Expired - Lifetime
- 1986-11-04 NL NL8602784A patent/NL8602784A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FR2590171A1 (en) | 1987-05-22 |
PT81631A (en) | 1986-01-01 |
BE903736A (en) | 1986-03-14 |
IT8667010A0 (en) | 1986-01-08 |
DE3545620A1 (en) | 1987-05-21 |
CH667011A5 (en) | 1988-09-15 |
NL8602784A (en) | 1987-06-16 |
PT81631B (en) | 1988-04-21 |
GR852917B (en) | 1986-04-07 |
IT1191985B (en) | 1988-03-31 |
FR2590171B1 (en) | 1988-02-12 |
CA1271424A (en) | 1990-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100360674B1 (en) | Herbal composition for preventing and treating dementria | |
FR2527446A1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF PAPAINE AND CITRIC ACID, WHICH CAN BE TAKEN IN A FOOD OR BEVERAGE | |
EP1289538A2 (en) | Compositions for enhancing therapeutic effects, containing herbals and/or nutritional supplements and/or minerals and/or vitamins | |
LU86184A1 (en) | FOOD SUPPLEMENT COMPOSITION FOR NATUROTHERAPY | |
FR2584929A1 (en) | Nutritional supplement composition based on Fraxinus excelsior leaves for nature-cure therapy | |
Alam et al. | Therapeutic use of Withania somnifera | |
JP2004000171A (en) | Functional food product containing maca | |
RU2743292C1 (en) | Agent for treating cholelithiasis and urolithiasis | |
EP0959892B1 (en) | Use of pvp or povidone for reducing bowel distension | |
Null | The complete encyclopedia of natural healing | |
RU2214240C1 (en) | Method for treatment of patients with psoriasis in combination with chronic opisthorchiasis | |
JP7379648B1 (en) | Constitution improving agent containing black bean tree | |
TWI488635B (en) | The new use of protect alcohol-induced hepatic injury by black garlic | |
JP4892833B2 (en) | Fat absorption inhibitor | |
FR2666228A1 (en) | Composition for the treatment of excessive weight and/or of cellulite | |
Kopf | Dry eye syndrome Treatment with Homeopathy and Schuessler salts (homeopathic cell salts): A homeopathic and naturopathic guide | |
Kundrat | Herbs and athletes | |
KR20010017629A (en) | Composition of healthfood for stamina-enhancement | |
WO2007007958A1 (en) | Herbal pharmaceutical composition for regenerative agent of cartilaginous tissue and treatment of osteoarthritis | |
Brown et al. | A Practical Approach to Herbs and Nutrients in Psychiatry | |
JPH0892109A (en) | Zoo/phytocrude-drug | |
Hobbs | Natural Therapy for Your Liver: Herbs and Other Natural Remedies for a Healthy Liver | |
Buchanan | The Acute Effects of Shred Matrix on Hemodynamic Responses, Substrate Utilization, Endurance, Arterial Compliance, and Body Water Distribution | |
JP3403576B2 (en) | Health drink and method for producing the same | |
No | 2. What is Shilajit? 10 |